Longeveron Inc.

NasdaqCM LGVN

Longeveron Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -142.15%

Longeveron Inc. Return on Equity (ROE) is -142.15% for the Trailing 12 Months (TTM) ending September 30, 2024, a 2.22% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Longeveron Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -145.38%, a -128.26% change year over year.
Longeveron Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -63.69%, a 16.20% change year over year.
Longeveron Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -76.00%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqCM: LGVN

Longeveron Inc.

CEO	Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
IPO Date	Feb. 12, 2021
Location	United States
Headquarters	1951 NW 7th Avenue
Employees	23
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Key trends

Past 5 years